Solvay expands development pact with Wyeth

Solvay and Wyeth Pharmceutical are expanding their existing neuroscience co-development and co-commercialization agreement to include research in neuroscience. The neuroscience co-development and co-commercialization partnership announced in April 2004 between Solvay and Wyeth resulted in an NDA for bifeprunox for the treatment of patients with schizophrenia. Meanwhile development continues on two other early-phase neuroscience projects, SLV313 and SLV314, which were part of that agreement.

- check out the release on the deal

Related Articles:
Solvay earns $25M as obesity drug advances. Report
Wyeth licenses Pharmacopeia's JAK3 program. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.